Comparing New England Nuclear (LNTH) and Achieve Life Sciences (ACHV)
New England Nuclear (NASDAQ: LNTH) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.
Institutional and Insider Ownership
90.6% of New England Nuclear shares are owned by institutional investors. Comparatively, 3.8% of Achieve Life Sciences shares are owned by institutional investors. 1.2% of New England Nuclear shares are owned by company insiders. Comparatively, 35.8% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares New England Nuclear and Achieve Life Sciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|New England Nuclear||$331.38 million||1.88||$123.38 million||$1.00||16.45|
|Achieve Life Sciences||$5.06 million||3.33||-$10.58 million||N/A||N/A|
New England Nuclear has higher revenue and earnings than Achieve Life Sciences.
Volatility & Risk
New England Nuclear has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500.
This table compares New England Nuclear and Achieve Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|New England Nuclear||37.23%||-68.13%||14.00%|
|Achieve Life Sciences||N/A||-138.65%||-118.38%|
This is a breakdown of current ratings and recommmendations for New England Nuclear and Achieve Life Sciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|New England Nuclear||0||1||3||0||2.75|
|Achieve Life Sciences||0||0||0||0||N/A|
New England Nuclear presently has a consensus target price of $24.00, suggesting a potential upside of 45.90%. Given New England Nuclear’s higher probable upside, research analysts plainly believe New England Nuclear is more favorable than Achieve Life Sciences.
New England Nuclear beats Achieve Life Sciences on 8 of the 11 factors compared between the two stocks.
About New England Nuclear
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
About Achieve Life Sciences
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
Receive News & Ratings for New England Nuclear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New England Nuclear and related companies with MarketBeat.com's FREE daily email newsletter.